Merck Seeks FDA Authorization For Antiviral Pill Which Reduces COVID-19 Deaths

Published by

On Monday, Merck, a pharmaceutical company based in the U.S., announced it is seeking authorization from the Food and Drug Administration (FDA) for its COVID-19 pill “for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization.” “The extraordinary impact of this pandemic demands that we move with unprecedented urgency, and that is what our teams have done by submitting this application for molnupiravir to the FDA within 10 days of receiving the data,” Robert Davis, CEO of Merck, said in a statement. Merck had stated previou…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *